Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Incyte Corporation(INCY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for INCY
11/06/2026: INCY (5-star) is currently NOT-A-BUY. Pass it for now.
Incyte Corporation is a mid-to-large cap biotechnology company focused on developing targeted therapeutics for oncology and inflammatory diseases. Its primary financial strength is the well-established commercial performance of its flagship product, Jakafi, which provides a solid revenue base. The company's main growth story centers on its ability to expand its JAK inhibition platform into new dermatological markets with products like Opzelura. However, investors must monitor risks related to the company's revenue concentration, the patent landscape for its core drug, and intense competition in the biopharma space. The stock may best suit growth-oriented investors interested in clinical innovation who are comfortable with the inherent volatility of the biotechnology sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Incyte's focus on innovative therapies and pipeline development appeals to those seeking long-term capital appreciation. |
| Momentum investor | Mixed fit | Momentum exposure is conditional on positive clinical data readouts or commercial growth surges. |
| Value investor | Weak fit | The company's valuation is often tied to pipeline potential rather than traditional price-to-earnings metrics. |
| Dividend investor | Weak fit | Incyte does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Biotech stocks face high clinical and regulatory risks, making them unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often react sharply to clinical trial results and FDA decisions. |
| Valuation risk | Medium | Future growth expectations are already priced in, which can lead to corrections if pipelines underperform. |
| Competition risk (JAK inhibition) | High | Several large players are developing competing therapies for similar indications. |
| Business quality | Medium | The company has a strong commercial product but faces concentration risk regarding its core portfolio. |
| Dividend income | Low / none | The company retains earnings for growth rather than returning cash to shareholders. |
| Execution risk | Medium | Successfully transitioning from a single-product company to a diversified entity is complex and carries execution risk. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 46.03% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 24.39B USD | Price to earnings Ratio 61.05 | 1Y Target Price 131.5 |
Price to earnings Ratio 61.05 | 1Y Target Price 131.5 | ||
Volume (30-day avg) 1.9M shares | Beta 0.78 | 52 Weeks Range 89.25 - 132.60 | Updated Date 11/08/2026 |
52 Weeks Range 89.25 - 132.60 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.96 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Hematology and Oncology | Jakafi, Pemazyre, and related royalty revenue. | Most of the company's money comes from selling drugs that treat specific types of blood cancers. |
| Inflammation and Dermatology | Opzelura cream for skin conditions. | This is the company's emerging growth area focused on dermatology. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 61.05 | Forward PE 13.42 | Enterprise Value 20.58B | Price to Sales(TTM) 4.06 |
Enterprise Value 20.58B | Price to Sales(TTM) 4.06 | ||
Enterprise Value to Revenue 3.42 | Enterprise Value to EBITDA 22.94 | Shares Outstanding 203.83M | Shares Floating 171.56M |
Shares Outstanding 203.83M | Shares Floating 171.56M | ||
Percent Insiders 1.83 | Percent Institutions 103.3 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.